Melatonin to improve sleep and thinking in people with cirrhosis
Official title: Effect of Supplemental Nightly Melatonin On REM and Cognition in Hepatic Encephalopathy (SNORE-HE) Trial
Run by Weill Medical College of Cornell University · NCT07046429 · Data updated 2026-11-12
This study will try one month of daily melatonin (compared with one month of thiamine) to see if it improves sleep and thinking in adults with cirrhosis and hepatic encephalopathy.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 18 (estimated) |
| Sponsor | Weill Medical College of Cornell University Academic / other |
| Locations | 1 site (New York, New York) |
| Status | Recruiting |
| Started | August 5, 2025 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | July 29, 2026 |
| Trial ID | NCT07046429 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with cirrhosis and clinically significant portal hypertension or decompensation who have covert or prior hepatic encephalopathy (PHES ≤ -4), disturbed sleep (PSQI ≥ 5), and a compatible smartphone are ideal candidates.
✕Probably not a fit
People who are regular melatonin users who won’t stop, have known sleep disorders like obstructive sleep apnea, BMI > 40, heavy current alcohol use, or are pregnant are excluded and unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a double-blind, randomized crossover pilot where participants take one month of melatonin and one month of thiamine in random order without knowing which they receive first. Participants will complete cognitive testing, quality-of-life surveys, wear a commercial sleep tracker, and undergo an overnight sleep study with salivary melatonin collection after each treatment period. The trial focuses on changes in sleep physiology—particularly REM sleep—as well as cognitive performance and patient-reported outcomes. The design allows within-subject comparison to limit variability in this small pilot cohort.
Why it matters
Potential benefit: If successful, melatonin could increase REM sleep and lead to measurable improvements in cognition and quality of life for patients with cirrhosis and hepatic encephalopathy.
How similar studies have gone: Melatonin has improved sleep in other populations, but its effects on REM sleep and cognition specifically in cirrhosis are largely untested, so this is a pilot exploration.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Cirrhosis with clinically significant portal hypertension or decompensation defined by Baveno VII criteria \[de Franchis R et al 2022\] * Adults over age 18 * CHE (defined by PHES≤ -4) or previously diagnosed HE * Disturbed sleep, with Pittsburgh Sleep Quality Index (PSQI) ≥5 * Possession of a "smart phone" with Bluetooth capability and ability to download the Oura application (Apple iOS version 14.0 or greater or Android version 8.0 or higher) Exclusion Criteria: * Use of melatonin regularly (3x per week) if unable/unwilling to discontinue for the study * Inability provide informed consent * Heavy current alcohol use (\>7 drinks weekly for women and 14 drinks weekly for men)' \-- Body mass index \>40 * Known prior sleep disorder including obstructive sleep apnea * Use of other prescription neuromodulating sleep aides * Self-reported pregnancy during study screening, as sleep physiology is different in this population
Where it's running
-
NewYork-Presbyterian/Weill Cornell Medical Center
New York, New York, United States Recruiting
Study contacts
- Principal investigator: Adam Buckholz, MD MS — NewYork-Presbyterian/Weill Cornell Medical College
- Study coordinator: Adam Buckholz, MD MS
- Email: apb9012@med.cornell.edu
- Phone: 646-962-5483
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis
This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.
-
Using inhaled amikacin to prevent pneumonia in cirrhosis patients on ventilators
This study is testing if inhaled amikacin can help prevent pneumonia in patients with cirrhosis who are on ventilators.
-
Using resistant potato starch to treat cirrhosis and hepatic encephalopathy
This study is testing if eating resistant potato starch can help improve gut health and symptoms in people with cirrhosis and hepatic encephalopathy.
-
Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis
This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.
-
EUS-guided coil and glue vs glue injection for bleeding gastric varices in cirrhosis
This trial tests whether using endoscopic ultrasound to guide coils plus glue works better than glue alone for stopping bleeding from gastric varices in adults with cirrhosis.
-
Coil-assisted small-diameter stent shunt reduction for refractory HE after TIPS
A coil-assisted, small-diameter covered-stent technique is being tested to see if it can safely and effectively reduce shunt flow and lessen recurrent hepatic encephalopathy in people with a prior TIPS.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.